Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma - Top-Institutions - MDSpire

Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma

  • By

  • Martin Zarba

  • Eddy Saad

  • Karl Semaan

  • Talal El Zarif

  • Evan Ferrier

  • Connor Wells

  • Razane El Hajj Chehade

  • Naveen S. Basappa

  • Hedyeh Ebrahimi

  • Mahrukh Huseni

  • Romain Banchereau

  • Rana R. McKay

  • Lori Wood

  • Benoit Beuselinck

  • Cristina Suárez

  • Kosuke Takemura

  • Aly-Khan A. Lalani

  • Haoran Li

  • Lavinia Anne Spain

  • Arnoud J. Templeton

  • Thomas B. Powles

  • Georg A. Bjarnason

  • Guillermo de Velasco

  • Toni K. Choueiri

  • Daniel Y. C. Heng

  • April 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Genitourinary Oncology
    • Translational Cancer Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Genitourinary Oncology
    • Cancer Epidemiology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Genitourinary Oncology
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Genitourinary Oncology
    • Immuno-oncology

  • #5

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Medical Oncology
    • Genitourinary Oncology
    • Cancer Genomics

Original Source(s)

Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma

  • by Martin Zarba, Eddy Saad, Karl Semaan, Talal El Zarif, Evan Ferrier, Connor Wells, Razane El Hajj Chehade, Naveen S. Basappa, Hedyeh Ebrahimi, Mahrukh Huseni, Romain Banchereau, Rana R. McKay, Lori Wood, Benoit Beuselinck, Cristina Suárez, Kosuke Takemura, Aly-Khan A. Lalani, Haoran Li, Lavinia Anne Spain, Arnoud J. Templeton, Thomas B. Powles, Georg A. Bjarnason, Guillermo de Velasco, Toni K. Choueiri, Daniel Y. C. Heng

  • April 15, 2026

Related Content

Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis

Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China